
    
      This study will be a Phase 2, double-blind, randomized, placebo-controlled study in up to 150
      participants. Participants will be randomized in a 2:1 ratio and will receive a once-weekly
      subcutaneous (SC) treatment with either IONIS-AGT-LRx or matching placebo. The length of
      participation in the study will be approximately 29 weeks, which includes an up to 4-week
      screening period, a 12-week treatment period, and a 13-week post-treatment period.
    
  